Meiji Seika Pharma

Meiji Seika Pharma is a Japanese pharmaceutical company and a subsidiary of Meiji Holdings. Its business is centered on prescription medicines, vaccines, infectious-disease treatments, central nervous system medicines, allergy products, and selected over-the-counter healthcare products. The company is associated with the wider Meiji corporate group, whose activities also include food and dairy businesses, but Meiji Seika Pharma operates as the group's dedicated pharmaceutical company. The company's corporate history is connected to the earlier Meiji Seika organization and to the development of Meiji's healthcare and pharmaceutical activities. A major structural change took place in 2009, when Meiji Seika Kaisha and Meiji Dairies Corporation established Meiji Holdings as a joint holding company. In 2011, the food and healthcare businesses were transferred to a newly formed Meiji Co., Ltd., while the pharmaceutical operation was reorganized under the name Meiji Seika Pharma Co., Ltd. This separation created a clearer distinction between the group's consumer food businesses and its medicines business. Meiji Seika Pharma has traditionally emphasized infectious disease as one of its principal areas of strength. Its portfolio includes antibacterial medicines, treatments for depression and obsessive-compulsive disorder, vaccines, and allergy medicines. The company also participates in research and development involving generic anticancer medicines and biosimilars, working with partner organizations in these fields. Its activities therefore combine established branded products, generic-drug development, biologics-related research, and healthcare products sold through pharmaceutical and consumer channels. The company has expanded its international reach through acquisitions and partnerships. In 2004, the broader Meiji organization acquired the Stauffer Biscuit Company in the United States, an event connected to the group's wider business history rather than solely to the modern pharmaceutical entity. In 2014, Meiji acquired Medreich, an Indian generic-pharmaceutical company with sales activities spanning Europe, Asia, and Africa. The Medreich transaction strengthened Meiji's presence in international generic medicines and complemented its Japanese pharmaceutical base. Meiji Seika Pharma's market identity is consequently broader than that of a narrowly focused specialty-drug developer. It combines a Japanese domestic pharmaceutical franchise with international generic-drug capabilities and research interests in biosimilars and oncology. The company is particularly associated with infectious-disease medicines, while also maintaining offerings in psychiatric medicine, vaccines, allergy treatment, and other therapeutic categories. Public reference material identifies it as a leading Japanese participant in infectious disease, including an 18 percent market-share figure, although the applicable market definition and reporting period are not specified in the available material. The company remains an active, unlisted subsidiary of Meiji Holdings.

Meiji Seika Pharma's history is rooted in the earlier Meiji Seika organization and its development of food, healthcare, and pharmaceutical activities in Japan. The modern company should be understood within the broader Meiji group rather than as an entirely separate enterprise with an independently documented origin date. Available reference material traces the pharmaceutical business's background to the earlier Meiji organization, while identifying the present corporate form as the result of a later reorganization. A significant stage in the group's development came in 2004, when Meiji acquired the Stauffer Biscuit Company, based in York, Pennsylvania. This transaction was part of Meiji's broader corporate history and illustrates that the group operated across more than one consumer and healthcare category. It was not, however, a pharmaceutical acquisition and should not be treated as the origin of Meiji Seika Pharma's medicines business. On April 1, 2009, Meiji Seika Kaisha and Meiji Dairies Corporation established Meiji Holdings as a joint holding company. The holding-company structure brought the two organizations under a common corporate framework and later became the basis for separating the group's food activities from its pharmaceutical operations. Meiji Holdings subsequently became a constituent of the Nikkei 225 index, although Meiji Seika Pharma itself is an unlisted subsidiary rather than a separately traded public company. Two years later, on April 1, 2011, the group's food and healthcare business was transferred to Meiji Co., Ltd. At the same time, the pharmaceutical operation was reorganized and adopted the name Meiji Seika Pharma Co., Ltd. This reorganization clarified the company's role as the pharmaceutical arm of Meiji Holdings. Its activities include prescription medicines, vaccines, infectious-disease treatments, central nervous system products, allergy medicines, and selected over-the-counter products. Infectious disease has remained a central area of the company's market identity. Reference material describes Meiji Seika Pharma as a leading Japanese participant in this field and attributes an 18 percent market share to it, though the relevant market scope and date are not stated in the available source. The company also markets treatments for depression and obsessive-compulsive disorder, as well as vaccines and allergy medicines. Beyond established products, it conducts or supports research into generic anticancer medicines and biosimilars with partner organizations. The company's international expansion gained a further step in 2014, when Meiji acquired Medreich, an Indian company active in generic pharmaceuticals and selling products in Europe, Asia, and Africa. The reported purchase price was $290 million. Medreich gave the Meiji group an additional platform for international generic-pharmaceutical operations and complemented Meiji Seika Pharma's Japanese prescription-drug business. Today, Meiji Seika Pharma operates as an active pharmaceutical subsidiary of Meiji Holdings, headquartered in Tokyo. Its profile combines domestic Japanese medicines expertise, infectious-disease capabilities, vaccines and specialty therapeutic areas, and an international orientation in generic medicines and related development. The available reference material does not provide a complete chronology of individual product launches, executive appointments, or current financial performance, so those details are not added here.

• 2014

  Acquisition of Medreich

  [1]Meiji Seika Pharmaen.wikipedia.org

  Meiji acquired Medreich, an Indian generic-pharmaceutical company serving markets in Europe, Asia, and Africa.

• 2011

  Pharmaceutical-business reorganization

  [1]Meiji Seika Pharmaen.wikipedia.org

  The food and healthcare business moved to Meiji Co., Ltd., and the pharmaceutical operation became Meiji Seika Pharma Co., Ltd.

• 2009

  Formation of Meiji Holdings

  [1]Meiji Seika Pharmaen.wikipedia.org

  Meiji Seika Kaisha and Meiji Dairies Corporation established Meiji Holdings as a joint holding company.

• 2004

  Acquisition of Stauffer Biscuit Company

  [1]Meiji Seika Pharmaen.wikipedia.org

  Meiji acquired the Stauffer Biscuit Company in York, Pennsylvania, as part of the wider group's corporate development.

A Japanese pharmaceutical company with a strong infectious-disease focus, complemented by prescription medicines in central nervous system and allergy care, vaccines, over-the-counter products, and international generic-pharmaceutical development.

• Prescription pharmaceuticals

  Infectious-disease medicines

  Infectious-disease treatment is a central part of Meiji Seika Pharma's pharmaceutical identity. The company is associated with antibacterial and related prescription medicines and is described in reference material as a leading Japanese participant in the infectious-disease field. The available source does not identify a complete product-by-product list or provide sufficient information to name individual current brands reliably.

• Prescription pharmaceuticals

  Central nervous system medicines

  The company's central nervous system portfolio includes medicines used in psychiatric care. Reference material specifically identifies treatments for depression and obsessive-compulsive disorder among the company's marketed therapies, but does not provide a sufficiently detailed current product catalog for individual brand names.

• Vaccines

  Vaccines

  Vaccines form part of Meiji Seika Pharma's healthcare portfolio and support its broader infectious-disease positioning. The available reference identifies vaccines as a marketed category but does not specify individual vaccine products, indications, or launch dates.

• Prescription and over-the-counter medicines

  Allergy medicines

  Meiji Seika Pharma markets medicines for allergy-related conditions alongside its infectious-disease and central nervous system products. Available source material confirms the category but does not provide enough detail to identify the complete range or particular current formulations.

• Generic and biologic medicines

  Generic anticancer medicines and biosimilars

  The company conducts research into generic anticancer medicines and biosimilars with partner organizations. These activities represent a development and research focus in addition to the company's established marketed portfolio. The available material does not specify individual compounds, products, partners, or regulatory milestones.

• Over-the-counter medicines

  Over-the-counter healthcare products

  Over-the-counter products are part of Meiji Seika Pharma's stated business scope. They complement the company's prescription-pharmaceutical activities, although the available reference does not identify particular current OTC brands or provide a complete product breakdown.

• 2014

  Acquisition of MedreichM&A

  Background

  Meiji sought to expand its international generic-pharmaceutical capabilities and geographic reach.

  Action taken

  Meiji acquired Medreich, an Indian generic-pharmaceutical company with sales activities in Europe, Asia, and Africa.

  Aftermath

  The acquisition strengthened Meiji's international platform for generic pharmaceuticals and complemented its Japanese pharmaceutical operations.

  Reported acquisition price. $290 million (2014 acquisition)

  Source

• 2011

  Separation of food and pharmaceutical operationsStrategy

  Background

  The Meiji group reorganized its food, healthcare, and pharmaceutical activities after the creation of Meiji Holdings.

  Action taken

  The food and healthcare business was transferred to Meiji Co., Ltd., while the pharmaceutical company was reorganized as Meiji Seika Pharma Co., Ltd.

  Aftermath

  Meiji Seika Pharma became the group's dedicated pharmaceutical company, with a focus on prescription medicines, vaccines, infectious disease, and related healthcare areas.

  Source

• 2009

  Creation of a joint holding-company structureStrategy

  Background

  Meiji Seika Kaisha and Meiji Dairies Corporation sought a common corporate structure for their businesses.

  Action taken

  The companies established Meiji Holdings as a joint holding company on April 1, 2009.

  Aftermath

  The structure preceded the later separation of the food business from the pharmaceutical operation and placed Meiji Seika Pharma within the Meiji Holdings group.

  Source

1. 1Meiji Seika Pharmaen.wikipedia.org
2. 2Meiji Seika Pharma official websitemeiji-seika-pharma.co.jp